Pfizer Makes First-Line Case for Tukysa in Breast Cancer

Pfizer makes first-line case for Tukysa in breast cancer

Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

Pfizer presents data for Tukysa in HER2-positive breast cancer - European Biotechnology Magazine

Pfizer’s Tukysa improves progression-free survival in first-line HER2-positive breast cancer, especially in HR-negative patients, with manageable safety. Data were shown at the 2025 San Antonio Breast Cancer Symposium. Pfizer’s Tukysa improves progression-free survival in first-line HER2-positive breast cancer, especially in HR-negative patients, with manageable safety.

Tucatinib/HP Maintenance Boosts PFS in Metastatic HER2+ Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.

Maintenance Tucatinib Combo Yields PFS Extension in Advanced HER2+ Breast Cancer

“HER2CLIMB-05 has demonstrated that the addition of tucatinib to HP represents an enhanced frontline maintenance therapy option for patients with HER2-positive metastatic breast cancer,” said Erika Hamilton, MD.

Tucatinib Enhances First-Line Maintenance Outcomes in HER2-Positive Metastatic Breast Cancer

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.